Faye Elliott

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

John Burn, Anne‐Marie Gerdes, Finlay Macrae et al. · The Lancet · 2011 · 951 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

<i>KRAS</i> and <i>BRAF</i> Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

Susan D. Richman, Philip Chambers, Faye Elliott et al. · Journal of Clinical Oncology · 2009 · 569 citations

Medicine, Molecular Genetics, Oncology +17

Cancer prevention with aspirin in hereditary colorectal cancer (Lynch syndrome), 10-year follow-up and registry-based 20-year data in the CAPP2 study: a double-blind, randomised, placebo-controlled trial

John Burn, Harsh Sheth, Faye Elliott et al. · The Lancet · 2020 · 403 citations · Full text

Medicine, Pharmacotherapy, Preventive Medicine +16

Effect of Aspirin or Resistant Starch on Colorectal Neoplasia in the Lynch Syndrome

John Burn, D. Timothy Bishop, Jukka‐Pekka Mecklin et al. · New England Journal of Medicine · 2008 · 295 citations · Full text

Medicine, Oncology, Pharmacology +14

Serum 25-Hydroxyvitamin D ₃ Levels Are Associated With Breslow Thickness at Presentation and Survival From Melanoma

Julia Newton‐Bishop, Samantha Beswick, Juliette A. Randerson‐Moor et al. · Journal of Clinical Oncology · 2009 · 282 citations · Full text

Medicine, Nutrition, Oncology +17